| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Camptothecins
|
|---|---|
| References | |
| Additional Infomation |
Antibody-drug conjugates (ADCs) are monoclonal antibodies conjugated to cytotoxic drugs. They utilize antibodies that specifically target proteins on the surface of tumor cells, thus possessing tumor specificity and potency that conventional drugs cannot achieve. Designing effective ADCs for cancer treatment requires selecting appropriate targets, monoclonal antibodies targeting those targets, potent cytotoxic effector molecules, and conjugating the monoclonal antibody to a cytotoxic drug. Significant progress has been made in all these areas over the past decade, leading to the clinical approval of ado-trastuzumab emtansine and brentuximab vedotin. Currently, some promising ADCs are in late-stage clinical trials. Ongoing research focuses on finding better targets, more effective cytotoxic payloads, and further improving ADC linker technology. A deeper understanding of the mechanisms of ADC activity will help design rational combination therapies with other drugs, including immunotherapy. [1]
|
| Molecular Formula |
C43H49FN8O9
|
|---|---|
| Molecular Weight |
840.9
|
| Exact Mass |
840.36065
|
| CAS # |
2227350-99-2
|
| Related CAS # |
Val-Cit-PAB-Exatecan TFA; 2928571-44-0
|
| PubChem CID |
148111182
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
1
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
61
|
| Complexity |
1800
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C5[C@H](CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)NC(=O)OCC7=CC=C(C=C7)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)N)O
|
| InChi Key |
JRIHOFFBVWRHMO-NMNMEXSISA-N
|
| InChi Code |
InChI=1S/C43H49FN8O9/c1-5-43(59)27-15-32-36-25(17-52(32)39(55)26(27)19-60-40(43)56)34-29(13-12-24-21(4)28(44)16-31(49-36)33(24)34)51-42(58)61-18-22-8-10-23(11-9-22)48-37(53)30(7-6-14-47-41(46)57)50-38(54)35(45)20(2)3/h8-11,15-16,20,29-30,35,59H,5-7,12-14,17-19,45H2,1-4H3,(H,48,53)(H,50,54)(H,51,58)(H3,46,47,57)/t29-,30-,35-,43-/m0/s1
|
| Chemical Name |
[4-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methyl N-[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]carbamate
|
| Synonyms |
Val-Cit-PAB-Exatecan; 2227350-99-2; SCHEMBL23277722;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1892 mL | 5.9460 mL | 11.8920 mL | |
| 5 mM | 0.2378 mL | 1.1892 mL | 2.3784 mL | |
| 10 mM | 0.1189 mL | 0.5946 mL | 1.1892 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
